Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew R Janes

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Nature Biotechnology|July 13, 2011
Next-generation flow cytometryMatthew R Janes, Christian Rommel
Oncotarget|July 27, 2010
Targeting TOR dependence in cancerMatthew R Janes, David A Fruman
Science Signaling|April 23, 2009
Immune regulation by rapamycin: moving beyond T cellsMatthew R Janes, David A Fruman
Methods in Molecular Biology (Clifton, N.J.)|November 30, 2011
The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemiaMatthew R Janes, David A Fruman
Plos One|March 4, 2014
Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1Sharmila Mallya, Briana A Fitch, J Scott Lee, et al.
Molecular Endocrinology (Baltimore, Md.)|March 26, 2011
B-1 cell lymphoma in mice lacking the steroid and xenobiotic receptor, SXRStephanie C Casey, Edward L Nelson, Gina M Turco, et al.
Scientific Reports|September 27, 2018
An Internally Controlled Quantitative Target Occupancy Assay for Covalent InhibitorsRasmus Hansen, Sarah J Firdaus, Shuangwei Li, et al.
The Journal of Clinical Investigation|August 16, 2008
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cellsMichael G Kharas, Matthew R Janes, Vanessa M Scarfone, et al.
The Journal of Clinical Investigation|June 2, 2017
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cellsMichael G Kharas, Matthew R Janes, Vanessa M Scarfone, et al.
Nature Structural & Molecular Biology|May 16, 2018
The reactivity-driven biochemical mechanism of covalent KRAS<sup>G12C</sup> inhibitorsRasmus Hansen, Ulf Peters, Anjali Babbar, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Nature Biotechnology|July 13, 2011
Next-generation flow cytometryMatthew R Janes, Christian Rommel
Oncotarget|July 27, 2010
Targeting TOR dependence in cancerMatthew R Janes, David A Fruman
Science Signaling|April 23, 2009
Immune regulation by rapamycin: moving beyond T cellsMatthew R Janes, David A Fruman
Methods in Molecular Biology (Clifton, N.J.)|November 30, 2011
The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemiaMatthew R Janes, David A Fruman
Plos One|March 4, 2014
Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1Sharmila Mallya, Briana A Fitch, J Scott Lee, et al.
Molecular Endocrinology (Baltimore, Md.)|March 26, 2011
B-1 cell lymphoma in mice lacking the steroid and xenobiotic receptor, SXRStephanie C Casey, Edward L Nelson, Gina M Turco, et al.
Scientific Reports|September 27, 2018
An Internally Controlled Quantitative Target Occupancy Assay for Covalent InhibitorsRasmus Hansen, Sarah J Firdaus, Shuangwei Li, et al.
The Journal of Clinical Investigation|August 16, 2008
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cellsMichael G Kharas, Matthew R Janes, Vanessa M Scarfone, et al.
The Journal of Clinical Investigation|June 2, 2017
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cellsMichael G Kharas, Matthew R Janes, Vanessa M Scarfone, et al.
Nature Structural & Molecular Biology|May 16, 2018
The reactivity-driven biochemical mechanism of covalent KRAS<sup>G12C</sup> inhibitorsRasmus Hansen, Ulf Peters, Anjali Babbar, et al.
Pageof 3